2,3,3',4',6-pentachlorobiphenyl (PCB 126) is a highly persistent and toxic polychlorinated biphenyl (PCB) congener. It is a potent endocrine disruptor and has been linked to various health problems, including cancer, reproductive disorders, and immune suppression. The compound is synthesized through chlorination of biphenyl and is often found in industrial waste and contaminated soil and water. Its persistence and toxicity have led to its inclusion in the Stockholm Convention on Persistent Organic Pollutants, which aims to eliminate or restrict its production and use. Extensive research on PCB 126 focuses on its environmental fate, toxicity, and potential health risks. This research is essential for understanding its environmental impact and developing strategies for its remediation and prevention.'
| ID Source | ID |
|---|---|
| PubMed CID | 38015 |
| SCHEMBL ID | 463759 |
| MeSH ID | M0102358 |
| Synonym |
|---|
| 2,3,3',4',6-pentachloro-1,1'-biphenyl |
| 1,1'-biphenyl, 2,3,3',4',6-pentachloro- |
| chlorobiphenyl 110 |
| 2,3,3',4',6-pentachlorobiphenyl |
| pcb 110 |
| 1,2,4-trichloro-3-(3,4-dichlorophenyl)benzene |
| 97rwu5j04p , |
| 38380-03-9 |
| unii-97rwu5j04p |
| pcb no 110 |
| 2',3,3',4,6'-pentachlorobiphenyl |
| 3,4,2',3',6'-pentachlorobiphenyl |
| 2,3,6,3',4'-pentachlorobiphenyl |
| SCHEMBL463759 |
| ARXHIJMGSIYYRZ-UHFFFAOYSA-N |
| DTXSID3038307 , |
| pcb no 110, analytical standard |
| pcb no. 110 |
| pcb no. 110 10 microg/ml in isooctane |
| Q27272032 |
| dtxcid1018307 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chlorobiphenyl 110 (2,3,3',4',6-pentaCB) was investigated in weanling female rats dosed ip on days 21 and 22 and killed on day 23 of age." | ( Hepatic enzyme induction and acute endocrine effects of 2,3,3',4',6-pentachlorobiphenyl in prepubertal female rats. Hansen, LG; Li, M; Rhine, C, 1998) | 0.55 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||